Abstract
We study the impact of college reopening in Fall 2020 on county-level COVID-19 cases and deaths using the information of 1,076 randomly chosen four- and two-year undergraduate degree-granting colleges from the National Center for Education Statistics. These institutions include public, private nonprofit, and for profit schools from 50 US states and the District of Columbia. We match college and county characteristics using several methods and calculate the average treatment effects of three teaching modalities: in-person, online, and hybrid on COVID-19 outcomes up to two months after college reopening. In pairwise comparison, colleges reopened with in-person teaching mode were found to have about 35 percentage points more cases within 15 days of reopening, compared to those that reopened online, and the gap widens over time at a decreasing rate. Death rates follow the pattern with a time lag. However, colleges with hybrid mode reach up to the rates of in-person mode after some time. We also find that greater endowment and student population, bigger class size, and fewer Republican voters in the county are major predictors of choosing remote teaching modes over in-person.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding was received for the preparation of this manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This research does not include any human subject.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Methods are explained further. New variables were included in the analysis for robustness.
Data Availability
All data used are publicly available and do not include any individual level information.
